Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.

Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W
Dig Dis Sci. 2010 55 (12): 3304-14

PMID: 20300841 · PMCID: PMC2890301 · DOI:10.1007/s10620-010-1187-4

Esophageal adenocarcinoma is an aggressive malignancy with a poor outcome, and its incidence continues to rise at an alarming rate. Current treatment strategies combining chemotherapy, radiation, and surgery are plagued with high rates of recurrence and metastasis. Multiple molecular pathways including the epidermal growth factor receptor, vascular endothelial growth factor, v-erb-b2 erythroblastic leukemia viral oncogene homolog (ERBB2), and Aurora kinase pathways are activated in many esophageal adenocarcinomas. In many cases, these pathways have critical roles in tumor progression. Research on the mechanisms by which these pathways contribute to disease progression has resulted in numerous biologic agents and small molecules with the potential to improve outcome. The promise of targeted therapy and personalized medicine in improving the clinical outcome is now closer than it has ever been.

MeSH Terms (15)

Adenocarcinoma Angiogenesis Inhibitors Antineoplastic Agents Aurora Kinases Barrett Esophagus Clinical Trials as Topic Combined Modality Therapy Disease Progression ErbB Receptors Esophageal Neoplasms Esophagectomy Humans Molecular Targeted Therapy Protein-Serine-Threonine Kinases Treatment Outcome

Connections (2)

This publication is referenced by other Labnodes entities: